Conclusion: A very high incidence of MIS-C, estimated 5.8/100 000 persons under the age of 19 with a predominantly cardiac involvement but very good outcome was noted in European Caucasian population in a nationwide cohort study in Slovenia. Attention to newly described pancreatic involvement should be raised.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2021-eular.3022

RAYNAUD’S PHENOMENON IN A SINGLE CENTER COHORT OF TURKISH CHILDREN
Ş. Çağlayan1, F. Demirı1, B. Sancar1, K. Uluı1, T. Çoykunerı1, B. Sözeriı1.1Health Sciences University, Umranıye Training and Research Hospital, Pediatric Rheumatology, Istanbul, Turkey

Background: Raynaud’s phenomenon (RP) is a vasospastic condition characterized by episodic color changes of blanching, cyanosis, and hyperemia of the extremities of the body

Objectives: We aim to examine the clinical presentation, capillaroscopic findings and disease associations of Raynaud’s phenomenon (RP) in pediatric patients

Methods: We retrospectively enrolled a single-center cohort of 247 consecutive pediatric patients with RP admitted to Umranıye Training and Research Hospital, Pediatric Rheumatology Clinic, Istanbul, Turkey, since 2016. Medical records were analyzed for clinical presentation, disease associations, and physical examination and laboratory findings.

Results: We reported 247 patients (152 female, 95 male) with RP. Their mean age at disease onset was 14.5±2.21 years. In patients with secondary RP syndrome (51.8%), color changes were more in patients with secondary RP (p=0.00). The presence of antinuclear antibodies and abnormal nailfold capillaries were more seen in patients with secondary RP (28% vs 74% and 35.3% vs 66.7, respectively p=0.00). Digital ulcer was detected 5.2% of patients (mostly secondary). Out of 247, 31 patients were treated with low-dose aspirin, 47 with calcium blockers, 25 with low-dose aspirin and calcium blockers, 16 with iloprost and/or bosentan, while the remaining 140 did not receive any drug.

Conclusion: Similar to adults, RP is more common in girls without an underlying disease. In patients with secondary RP, the symptoms. It has been shown that in patients with secondary RP, symptoms begin at a younger age and the ANA positivity and abnormal nailfold capillaries correlate.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2021-eular.3076

DIFFERENCES IN CLINICAL MANIFESTATION AND DISEASE ACTIVITY OF PEDIATRIC BEHÇET DISEASE: A CROSS-SECTIONAL COHORT COMPARISON BETWEEN TURKEY AND UNITED STATES
E. Demirkıya1, M. Romano1, C. Swearengen2, O. Kasapcogu3, B. Makay4, S. Özern1, Y. Yazici5, Ş. Sözen5, Y. Yazici6.

1Department of Medicine, Rheumatology, New York University-Cornell Medical Center, New York, United States of America
2London Hospital for Joint Diseases, Rheumatology, New York, United States of America
3Istanbul University-Cerrahpaşa, Paediatric Rheumatology, Istanbul, Turkey
4Dokuz Eylül University, Paediatric Rheumatology, Izmir, Turkey
5Hacettepe University, Ankara, Paediatric Rheumatology, Ankara, Turkey
6University New York School of Medicine, Rheumatology, New York, United States of America

Background: Behçet disease (BD) is a systemic inflammatory disease which is rare in children. It is also known a higher prevalence along the Silk Road and the eastern Mediterranean, especially in Turkey. Despite the presence of diagnostic criteria, the diagnosis of pediatric BD is still difficult due to atypical findings and the heterogeneity of the disease. While descriptive cohort studies in pediatric BD exist, direct comparison studies of clinical manifestations and disease activity between patients from different countries are scarce.

Objectives: We aimed to compare the main clinical features and activity of pediatric BD patients from Turkey versus United States (US).

Methods: The BD was diagnosed before 18 years of age and based on expert opinion. Disease activity was assessed with Physician Global Assessment (PhGA), Parents/Patient Global Assessment (PWPGA) and Behçet’s Syndrome Activity Scale (BSAS) were administered to patients from both countries.

Results: A total of 161 patients were included (61 from Turkey; 100 from US). Males were more prevalent among patients from Turkey than among patients from US (63.9% vs. 32%, respectively, p < 0.001). Disease duration at the diagnosis was significantly longer in US (p=0.002). Oral aphthosis duration was the most common symptom in both groups (96.7% for Turkey and 73% for US), however a significant difference was found (p=0.001). Genital ulcers were documented in 47% of US patients and in 41.4% of Turkish patients (p=0.5). There were significant difference between two groups with regards to the ocular involvement: uveitis and posterior uveitis were more frequently in Turkish patients (p=0.001 respectively) while retinal vasculitis was seen in US patients (p<0.001). Erythema nodosum occurred more frequently in Turkish group (p=0.001). The pathergy test was reported as positive in 22 (37.3%) patients in Turkey and 2 (2.3%) in USA in our study (p=0.001). Gastrointestinal and neurological involvement did not differ between cohorts. The rate of colchicine and oral steroids was similar. Azathioprine, cyclosporine and methotrexate usage was more frequent in Turkey (p=0.003, respectively and infliximab was administered just in the US cohort (p = 0.002). PhGA and BSAS scores were higher in patients from Turkey (p=0.003 and p=0.017 respectively) and no significant differences were seen in PWPGA scores.

Conclusion: Disease activity and clinical features seem to be different between the two countries which may be linked to the environmental factors, referral patterns and immune system responses in the expression of this disease. The diagnosis of BD in the US was based on both fulfilling the ISBD criteria and in cases when criteria were not met, based on treating physician assessment, which can explain some of the differences in disease presentation. In addition, there were differences in regard to clinical practice and treatment patterns between two countries. Increasing knowledge about heterogeneity of BD will improve the ability of diagnosis, development of new diagnostic criteria, and management of BD.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2021-eular.3132

DIFFERENCES IN CLINICAL MANIFESTATION AND DISEASE ACTIVITY OF PEDIATRIC BEHÇET DISEASE: A CROSS-SECTIONAL COHORT COMPARISON BETWEEN TURKEY AND UNITED STATES